论文部分内容阅读
目的 观察紫杉醇联合卡铂治疗晚期恶性肿瘤的疗效及不良反应。方法 2 7例晚期恶性肿瘤患者随机分为两组 ,A组为紫杉醇 135mg/m2 第 1天应用 ,3周重复。B组为紫杉醇 6 0～ 70mg/m2 第 1、8、15天应用 ,4周重复 ,均联合卡铂 ,至少 2周期评价疗效。结果 初治 9例 (均为晚期肺癌 )有效率达 5 5 .6 % ,复治 18例 ,有效率达 4 4 .4 % ,总有效率达 5 1.9% ,其中 5例获CR ,另外 ,B组骨髓抑制明显比A组为轻 (P <0 .0 5 )。结论 紫杉醇联合卡铂对晚期恶性肿瘤疗效肯定 ,特别是初治的晚期肺癌疗效更为显著。另外 ,紫杉醇分次应用疗效不减 ,但骨髓抑制减轻
Objective To observe the efficacy and side effects of paclitaxel combined with carboplatin in the treatment of advanced malignancies. Methods Twenty-seven patients with advanced malignant tumor were randomly divided into two groups. Group A received paclitaxel 135 mg / m2 on day 1 and repeated 3 weeks. Group B was paclitaxel 60 ~ 70mg / m2 on the 1st, the 1st and the 15th, the application was repeated for 4 weeks, both combined with carboplatin, at least 2 cycles to evaluate the curative effect. Results The initial effective rate of 9 cases (all advanced lung cancer) was 55.6%, retreatment of 18 cases, the effective rate of 44.4%, the total effective rate of 5 1.9%, of which 5 were CR, in addition, Bone marrow suppression was significantly lower in group B than in group A (P <0.05). Conclusion Paclitaxel combined with carboplatin is effective in the treatment of advanced malignancies, especially in the treatment of advanced lung cancer. In addition, paclitaxel sub-sub-treatment efficacy diminished, but reduced bone marrow suppression